NCT02045316 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Castro-Parodi M, Levi L, Dietrich V, Zotta E, Damiano AE
CFTR may modulate AQP9 functionality in preeclamptic placentas. Placenta. 2009 Jul;30(7):642-8. doi: 10.1016/j.placenta.2009.04.012. Epub 2009 May 28.
Damiano A, Zotta E, Goldstein J, Reisin I, Ibarra C
Water channel proteins AQP3 and AQP9 are present in syncytiotrophoblast of human term placenta. Placenta. 2001 Sep-Oct;22(8-9):776-81.
Damiano AE, Zotta E, Ibarra C
Functional and molecular expression of AQP9 channel and UT-A transporter in normal and preeclamptic human placentas. Placenta. 2006 Nov-Dec;27(11-12):1073-81. Epub 2006 Feb 9.
Damiano AE
Review: Water channel proteins in the human placenta and fetal membranes. Placenta. 2011 Mar;32 Suppl 2:S207-11. doi: 10.1016/j.placenta.2010.12.012. Epub 2011 Jan 5. Review.
Leung DN, Smith SC, To KF, Sahota DS, Baker PN
Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2001 May;184(6):1249-50.
Marino GI, Castro-Parodi M, Dietrich V, Damiano AE
High levels of human chorionic gonadotropin (hCG) correlate with increased aquaporin-9 (AQP9) expression in explants from human preeclamptic placenta. Reprod Sci. 2010 May;17(5):444-53. doi: 10.1177/1933719110361385. Epub 2010 Mar 10.

The Expression of Aquaporin 3, 8 and 9 in Placenta, Umbilical Cord and Fetal Membranes in Normal Pregnancies and Pregnancies Complicated by Preeclampsia: Perinatal and Neonatal Outcomes.

Details for clinical trial NCT02045316

Clinical trial NCT02045316 - References